Načítá se...
Hepatitis B Reactivation and Rituximab in the Oncology Practice
Rituximab use in hematology and oncology practice has significantly and positively improved the clinical outcomes in patients with a wide variety of B-cell lymphoproliferative disorders. However, emerging data reveal that there is a risk of viral hepatitis B reactivation in some patients treated wit...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227895/ https://ncbi.nlm.nih.gov/pubmed/20930099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0106 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|